{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreib54rn6uooyg4dctbrbe6m3lp64y4u6lz2vgiymwdo4evttaamipy",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mo4gyvkrflg2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiegjj2nc5htmsga5zhgui6o3ckibqpzwa74gzfre67ifxp7fq6e6i"
    },
    "mimeType": "image/jpeg",
    "size": 103431
  },
  "path": "/news/2026-06-ada-weekly-cagrilintide-semaglutide-diabetes.html",
  "publishedAt": "2026-06-12T14:20:04.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "Once-weekly cagrilintide, an amylin receptor agonist, plus semaglutide is efficacious for adults with type 2 diabetes inadequately controlled with diet and exercise, receiving metformin with or without a sodium glucose cotransporter 2 inhibitor (SGLT2i), and using basal insulin, according to three studies published online June 7 in The Lancet Diabetes & Endocrinology and The Lancet to coincide with the annual meeting of the American Diabetes Association, held from June 5 to 8 in New Orleans.",
  "title": "ADA: Once-weekly cagrilintide + semaglutide promising in type 2 diabetes"
}